Education
About Us
Working with TipRanks
Follow Us
Phreesia (PHR)
NYSE:PHR
PHR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.07 - $30.53
Previous CloseN/A
Volume173.69K
Average Volume (3M)488.08K
Market Cap
$1.53B
Enterprise ValueN/A
Total Cash (Recent Filing)$84.22M
Total Debt (Recent Filing)$17.80M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Sep 03, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding59,504,270
10 Day Avg. Volume620,558
30 Day Avg. Volume488,079
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)5.55
Price to Sales (P/S)0.00
P/FCF Ratio126.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.20Price Target Upside21.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Phreesia News
PremiumCompany Announcements
Phreesia Reports Strong Start to Fiscal 2026Bulls Say, Bears Say
Bulls Say
EarningsThe company reported a strong start to fiscal 2026, with largely in-line sales and continued strong operating leverage, which drove a 5% raise to full-year adjusted EBITDA guidance.
Financial PerformanceAdj-EBITDA rose 408%, significantly exceeding analyst estimates, and the company revised its adj-EBITDA range upward.
Revenue GrowthRevenue grew 14.5% as AHSCs grew 8.5% y/y and provider revenue/AHSC grew 5.2%.
Bears Say
Market RisksConcerns around pharma marketing budgets in the current policy environment as well as fears of potential delayed purchasing decisions from providers amid funding and reimbursement uncertainty have weighed a bit on the stock following the initial surge.
Network SolutionsThere is a slowdown in network solutions revenue growth, with a decrease to 16% in the quarter compared to 26% in fiscal 2025.
Regulatory RisksThere is potential risk to Phreesia’s life sciences product offerings in the event of regulatory changes to direct-to-consumer pharma marketing.
Ownership Overview
5.96% Insiders
37.27% Mutual Funds
31.93% Other Institutional Investors
11.68% Public Companies and Individual Investors
PHR FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest stock price was $17.07 and its highest was $30.53 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is $1.53B.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Sep 03, 2025 which is in 88 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on May 28, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.122 by $0.052.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Undervalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is -0.07.
How many shares outstanding does Phreesia have?
Phreesia has 59,504,270 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.122. Following the earnings report the stock price went down -6.613%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in PHR
Phreesia Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.20 (21.02% Upside)
$31.20 (21.02% Upside)
Blogger Sentiment
Bullish
PHR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 266.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.44%
12-Months-Change
Fundamentals
Return on Equity
-15.97%
Trailing 12-Months
Asset Growth
7.61%
Trailing 12-Months
Company Description
Phreesia
Phreesia (PHR) is a healthcare technology company that specializes in providing a comprehensive platform for patient intake and engagement. The company's solutions are designed to streamline the patient intake process, enhance patient communication, and improve the overall experience for both healthcare providers and patients. Phreesia's platform integrates with existing healthcare systems, offering services such as appointment scheduling, patient registration, insurance verification, and payment processing.
PHR Company Deck
PHR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Phreesia's earnings call shows a positive overall performance with strong revenue growth, improved EBITDA, and positive cash flows. However, there are some uncertainties regarding network solutions pacing and potential risks from legislative changes affecting pharmaceutical advertising revenue.Read More>PHR Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
PHR Stock 12 Month Forecast
Average Price Target
$31.20
▲(21.02%Upside)